Lilly Knocks On Wood: Transition of Zyprexa Dual Eligibles Moves Along Smoothly
This article was originally published in The Pink Sheet Daily
Lilly says that it is not hearing any "anecdotal stories" regarding troubles with transitioning dual eligibles taking the atypical antipsychotic to Medicare.
You may also be interested in...
Forthcoming cost-effectiveness analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness study could prove to be a boon for Zyprexa because of reduced hospitalization with Lilly’s atypical antipsychotic.
Two of the leading medical journals are offering opposing viewpoints on mandatory human papilloma virus vaccination, with experts contributing perspective pieces that directly reflect the larger political and social division over the issue
FDA's "not approvable" action on Merck's Vioxx follow-on Arcoxia for the treatment of symptoms of osteoarthritis could be indicative of a conservative regulatory climate at the agency